This study will assess the effectiveness of adding the drug bortezomib to the standard drug treatment for high risk (HR) acute lymphoblastic leukaemia (ALL) in children and adolescents who have relapsed. During the first month of relapse treatment, the child or adolescent will be randomly allocated to receive standard treatment with or without bortezomib. This will demonstrate if inclusion of bortezomib will improve the chance of a complete response if provided in first month of relapse treatment.
Disease Stage: Relapse
Patient Age Range: <18 years
Sample Size: 100-250
- International: Charite University Medicine Berlin
- National: ANZCHOG